Eton Pharmaceuticals Inc (OQ:ETON)

Oct 16, 2020 04:05 pm ET
Eton Pharmaceuticals Announces Closing of Public Offering
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000...
Oct 15, 2020 08:30 am ET
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for...
Oct 14, 2020 08:30 am ET
Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000...
Oct 13, 2020 04:01 pm ET
Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an...
Oct 08, 2020 08:00 am ET
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for...
Oct 06, 2020 04:05 pm ET
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that in tandem with its development and manufacturing partner...
Sep 29, 2020 06:49 pm ET
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Sep 25, 2020 08:00 am ET
FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%
LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander, which is one of the...
Sep 16, 2020 09:00 am ET
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner has not yet received a communication from the U.S. Food and Drug...
Aug 31, 2020 08:00 am ET
Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Ingrid Hoos as the company’s new Senior Vice President of...
Aug 12, 2020 08:30 am ET
Eton Pharmaceuticals Announces Second Quarter 2020 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the second quarter ended June 30, 2020 and provided an update on...
Aug 11, 2020 09:00 am ET
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner has not yet received a communication from the U.S. Food and Drug...
Aug 04, 2020 04:10 pm ET
Eton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday,...
Jul 30, 2020 08:00 am ET
Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has submitted a new drug application (NDA) for zonisamide oral suspension,...
Jul 27, 2020 07:30 am ET
Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has submitted a new drug application (NDA) for dehydrated alcohol injection,...
May 14, 2020 04:02 pm ET
Eton Pharmaceuticals Announces First Quarter 2020 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an update on...
May 07, 2020 08:00 am ET
Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today disclosed that it has been confirmed as the first filer of an Abbreviated New Drug Application...
May 06, 2020 04:30 pm ET
Eton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May...
May 04, 2020 08:00 am ET
Eton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice President of Sales...
Mar 27, 2020 07:00 am ET
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has acquired U.S. marketing rights to Alkindi® Sprinkle from Diurnal Group plc...
Mar 17, 2020 08:00 am ET
Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced positive bioequivalence study results for ET-101, its proprietary oral solution...
Mar 05, 2020 04:02 pm ET
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the fourth quarter ended December 31, 2019 and provided an update...
Feb 27, 2020 04:10 pm ET
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and operating results...
Feb 19, 2020 08:00 am ET
Eton Pharmaceuticals Provides Update on ET-105 Program
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET-105 product candidate, which is currently under review with the U.S....
Feb 13, 2020 04:05 pm ET
Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB...
Jan 21, 2020 07:00 am ET
Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion...
Dec 02, 2019 07:30 am ET
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Biorphen®, the first and only FDA-approved ready-to-use formulation of...
Nov 14, 2019 04:01 pm ET
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the third quarter ended September 30, 2019 and provided an update...
Nov 13, 2019 04:55 pm ET
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation. “We are...
Nov 06, 2019 04:05 pm ET
Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday,...
Oct 22, 2019 07:00 am ET
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S. Food and Drug Administration (FDA) has approved Biorphen®, the first and...
Sep 03, 2019 04:01 pm ET
Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in the Lake Street 3rd...
Aug 19, 2019 07:00 am ET
Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products today announced positive results from bioequivalence studies of ET-104, Eton’s proprietary oral liquid formulation of a molecule frequently used to treat a severe neurological condition.
Aug 06, 2019 04:01 pm ET
Eton Announces Second Quarter Financial Results and Highlights Business Progress
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the second quarter ended June 30, 2019 and provided an update on...
Aug 02, 2019 07:30 am ET
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian™ anti-microbial molecule for ophthalmic and otic...
Aug 01, 2019 08:01 am ET
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Aucta Pharmaceuticals' New Drug Application for ET-105, an innovative formulation...
Jul 30, 2019 08:01 am ET
Eton Pharmaceuticals to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2019 financial and operating results on Tuesday,...
Jul 25, 2019 07:30 am ET
Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30...
Jul 12, 2019 04:01 pm ET
Eton Pharmaceuticals Provides Update on EM-100 Program
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S Food and Drug Administration (FDA) provided Eton’s partner with a Complete...
Jun 13, 2019 04:01 pm ET
Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the Company has entered into an agreement with Aucta Pharmaceuticals, Inc to...
May 15, 2019 04:01 pm ET
Eton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 20th Annual B....
May 07, 2019 04:05 pm ET
Eton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
DEER PARK, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the first quarter...
Apr 30, 2019 04:30 pm ET
Eton Pharmaceuticals to Report First Quarter 2019 Financial Results on Tuesday, May 7, 2019
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2019 financial and operating results on Tuesday, May...
Mar 25, 2019 08:01 am ET
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a...
Mar 14, 2019 08:00 am ET
Eton Pharmaceuticals Submits New Drug Application for DS-200
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previously granted Fast...
Feb 21, 2019 08:00 am ET
Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in a fireside chat at...
Feb 19, 2019 06:00 am ET
Feb 19, 2019 06:00 am ET
Feb 11, 2019 08:01 am ET
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into an exclusive licensing and supply agreement with Sintetica...
Jan 24, 2019 04:10 pm ET
Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a licensing and supply agreement for ET-104, an innovative...
Dec 20, 2018 06:30 am ET
Eton Pharmaceuticals Reports Third Quarter Results and Business Update
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the third quarter ended September 30, 2018 and provided a business...
Nov 16, 2018 07:30 am ET
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced that it ranked 88th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North...
Nov 12, 2018 04:52 pm ET
Eton Pharmaceuticals Announces Pricing of Initial Public Offering
Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at a...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.